Hormonal variations in secondary amenorrhoea during the metyrapone test.
The occurrence of uterine bleeding following administration of Metyrapone in cases of secondary amenorrhoea and oligomenorrhoea led the authors to measure pituitary, gonadal and adrenal hormone levels, before and after the oral administration of this drug in sixteen patients, in an attempt to provide an interpretation of this phenomenon. There were expected changes in plasma ACTH and urinary 17-hydroxycorticosteroids, but no variations were noted in serum FSH and LH, plasma oestradiol and urinary oestrogens; the most important alterations occurred in plasma progesterone and urinary pregnanetriol levels. It is suggested that bleeding occurs because of the changes which are induced in plasma progesterone levels.
D000305:Adrenal Cortex Hormones / Q000652:urine; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000328:Adult; D000568:Amenorrhea / Q000097:blood / Q000503:physiopathology*; D003366:Cosyntropin / Q000494:pharmacology; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000652:urine; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation / Q000187:drug effects; D008797:Metyrapone / Q000494:pharmacology*; D009839:Oligomenorrhea / Q000503:physiopathology; D010901:Pituitary Function Tests; D011276:Pregnanediol / Q000652:urine; D011279:Pregnanetriol / Q000652:urine; D011374:Progesterone / Q000097:blood
D000305:Adrenal Cortex Hormones; D004967:Estrogens; D003366:Cosyntropin; D011279:Pregnanetriol; D011374:Progesterone; D004958:Estradiol; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011276:Pregnanediol; D008797:Metyrapone